Mayo Foundation for Medical Education and Research

University of Pittsburgh

Yasuhiro Ikeda

Stephen James Russell

John C Burnett, Jr

Alessandro Cataliotti

Jason M Tonne

Andre Terzic

Kazunori Koide

Amber A Mael

Timothy J Nelson

Yogish C Kudva

Almudena J Martinez Fernandez

Claire A Schreiber

Karol M Budzik

Toshie Sakuma

Sara J Holditch

Satsuki Yamada

Tayaramma Thatava

Patricia Devaux

This document provides methods and materials for treating cancer. For example, foamy viruses (e.g., simian foamy viruses) are provided as well as methods and materials for treating cancer using foamy viruses as an oncolytic agent.

Foamy viruses and methods of use

This document relates to methods and materials for increasing viral vector infectivity. For example, methods and materials for using spliceosome inhibitors (e.g., U2 snRNP spliceosome inhibitors such as meayamycin B or pladienolide derivative E7107) to increase viral vector (e.g., adeno-associated virus-based vector) infectivity are provided.

Methods and materials for increasing viral vector infectivity

This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.

Treating cardiovascular or renal diseases

This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided.

Method of treating heart tissue using induced pluripotent stem cells

This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.

Differentiating induced pluripotent stem cells into glucose-responsive, insulin-secreting progeny

Growing community of inventors

Rochester, MN, United States of America

Yasuhiro Ikeda